These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21417439)

  • 41. Co-delivery of siRNA and hypericin into cancer cells by hyaluronic acid modified PLGA-PEI nanoparticles.
    Li Y; Zhang J; Wang B; Shen Y; Ouahab A
    Drug Dev Ind Pharm; 2016; 42(5):737-46. PubMed ID: 26472259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy.
    Bi Y; Lee RJ; Wang X; Sun Y; Wang M; Li L; Li C; Xie J; Teng L
    Int J Nanomedicine; 2018; 13():5811-5822. PubMed ID: 30323583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cytological Study in vitro on Co-delivery of siRNA and Paclitaxel within Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Tumors].
    Huang R; Yao X; Chen Y; Sun X; Lin Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2016 Feb; 33(1):108-14. PubMed ID: 27382749
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes.
    Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H
    J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C; Liu W; Hu Y; Li W; Di W
    Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma.
    Liu WL; Green N; Seymour LW; Stevenson M
    Cancer Gene Ther; 2009 Oct; 16(10):764-75. PubMed ID: 19363466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GABA
    Ni S; Liu Y; Tang Y; Chen J; Li S; Pu J; Han L
    Carbohydr Polym; 2018 Jan; 179():135-144. PubMed ID: 29111036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression.
    Wei W; Lv PP; Chen XM; Yue ZG; Fu Q; Liu SY; Yue H; Ma GH
    Biomaterials; 2013 May; 34(15):3912-23. PubMed ID: 23453062
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.
    Jang SH; Wientjes MG; Au JL
    J Pharmacol Exp Ther; 2001 Mar; 296(3):1035-42. PubMed ID: 11181938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection.
    Walker T; Nolte A; Steger V; Makowiecki C; Mustafi M; Friedel G; Schlensak C; Wendel HP
    Eur J Cardiothorac Surg; 2013 Mar; 43(3):628-33; discussion 633-4. PubMed ID: 23152437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.
    Dong H; Yao L; Bi W; Wang F; Song W; Lv Y
    J Cancer Res Ther; 2015; 11(4):717-22. PubMed ID: 26881507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhanced antitumor efficacy of glutathione-responsive chitosan based nanoparticles through co-delivery of chemotherapeutics, genes, and immune agents.
    Zhang L; Li Q; Chen J; Tang C; Yin C
    Carbohydr Polym; 2021 Oct; 270():118384. PubMed ID: 34364626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis.
    Sun P; Huang W; Jin M; Wang Q; Fan B; Kang L; Gao Z
    Int J Nanomedicine; 2016; 11():4931-4945. PubMed ID: 27729789
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sphingosine kinase-2 silencing modulates sensitivity of HT-29 human colorectal cancer cells to paclitaxel-induced cell death through altering apoptosis-related proteins.
    Mu Y; Wang J; Li G
    Chem Biol Drug Des; 2023 Aug; 102(2):255-261. PubMed ID: 36929215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
    Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
    Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survivin is required for stable checkpoint activation in taxol-treated HeLa cells.
    Carvalho A; Carmena M; Sambade C; Earnshaw WC; Wheatley SP
    J Cell Sci; 2003 Jul; 116(Pt 14):2987-98. PubMed ID: 12783991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
    Montazeri Aliabadi H; Landry B; Mahdipoor P; Uludağ H
    Mol Pharm; 2011 Oct; 8(5):1821-30. PubMed ID: 21838308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [nm23-H1-siRNA enhances the chemosensitivity to liposome-encapsulated paclitaxel in lung adenocarcinoma cells in vitro].
    Yang XQ; Zhang ZM; Wang D; Wang G; Zeng LL; Yang ZZ
    Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):405-9. PubMed ID: 21875478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhanced transfection rates of small-interfering RNA using dioleylglutamide-based magnetic lipoplexes.
    Lee S; Shim G; Kim S; Kim YB; Kim CW; Byun Y; Oh YK
    Nucleic Acid Ther; 2011 Jun; 21(3):165-72. PubMed ID: 21749293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
    Shen H; Rodriguez-Aguayo C; Xu R; Gonzalez-Villasana V; Mai J; Huang Y; Zhang G; Guo X; Bai L; Qin G; Deng X; Li Q; Erm DR; Aslan B; Liu X; Sakamoto J; Chavez-Reyes A; Han HD; Sood AK; Ferrari M; Lopez-Berestein G
    Clin Cancer Res; 2013 Apr; 19(7):1806-15. PubMed ID: 23386691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.